Latest News & Features
Americas
Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex. 1 March 2017
Americas
The US Court of Appeals for the Federal Circuit has remanded a decision to the Patent Trial and Appeal Board concerning a dispute between LA Biomedical Research Institute and Eli Lilly. 1 March 2017
Big Pharma
The World Health Organization has published a list of antibiotic-resistant “priority pathogens”, a catalogue of 12 families of bacteria which it claims pose the greatest threat to human health. 28 February 2017
Americas
The US Court of Appeals for the Federal Circuit erred in holding that biosimilar applicants must give 180 days’ pre-marketing notice after an application has been approved by the US Food and Drug Administration, according to the acting solicitor general. 28 February 2017
Big Pharma
“The Unified Patent Court without Britain is a far less potent idea,” says Nick McDonald, partner of Potter Clarkson. 28 February 2017
Americas
Supplements company Akeso Health Sciences has filed a complaint against organic foods distributor United Natural Foods for patent infringement over a dietary supplement for patients suffering from migraines. 27 February 2017
Americas
Absorption Pharmaceuticals, a producer of premature ejaculation treatment, has filed a complaint against multinational consumer goods company Reckitt Benckiser over trade secret misappropriation. 27 February 2017
Americas
The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive. 24 February 2017
Americas
The Patent Trial and Appeal Board has upheld a patent covering Pozen’s Vimovo in a case against Kyle Bass’s organisation, the Coalition for Affordable Drugs. 24 February 2017
Biotechnology
According to the European Commission, if a biotech company crosses two plants to create a new plant through natural means, the outcome will not be patentable, explains Jane Wainwright of Potter Clarkson in a video interview with LSIPR. 23 February 2017